|Description||CBB1003, a piperazine derivative, has been found to be a histone demethylase LSD1 inhibitor that could restrain the proliferation and colony formation of CRC cell in mice. IC50: 10.54 uM.|
|Synonyms||CBB1003; SCHEMBL16273292; CS-3476|
|Solubility||10 mM in DMSO|
|Application||CBB1003 has been found to be a histone demethylase LSD1 inhibitor that could restrain the proliferation and colony formation of CRC cell in mice.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
GSK-J2, a benzazepin derivative, has been found to have poor activity as a JMJD3 inhibitor so that could be used in the biological study of GSK-J1 as a negative...
GSK2879552 has been found to be a LSD1 inhibitor that could have antineoplastic effect through restraining the growth of overexpressed tumor cells. It was just ...
A novel histone lysine demethylase 4D (KDM4D) inhibitor (IC50= 0.41±0.03 μM)
DDP-38003 trihydrochloride is the trihydrochloride salt of DDP-38003 which is a potent, selective, oral bioavailable irreversible inhibitor of KDM1A.
IOX1 is a potent and broad-spectrum inhibitor of 2OG oxygenases.
SP2509 inhibits the association of LSD1 with CoREST, increases promoter-specific H3K4Me3 and induces p53, p21 and C/EBPα. SP2509 also significantly inhibits the...
GSK3326595, also called as EPZ015938, is an orally available and specific inhibitor of protein arginine methyltransferase 5 (PRMT5) that potently inhibits tumor...
ML324 exhibits good Caco-2 cell permeability, and possesses excellent microsomal stability in the presence of both mouse and rat liver microsomes.
CBB1007, an amidino-guanidinium derivative, has been found to have biological activity in anticancer-study by acting as a LSD1 inhibitor. IC50: 5.27 uM.
CBB1003, a piperazine derivative, has been found to be a histone demethylase LSD1 inhibitor that could restrain the proliferation and colony formation of CRC ce...
NCGC00244536 is a potent KDM4A inhibitor (IC50= 10 nM) that inhibits the in vivo growth of tumors derived from PC3 cells and ex vivo human PCa explants.
GSK-J1 is a highly potent H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM in cell-free assays for JMJD3 (KDM6B) and UTX (KDM6A), respectively, ...
NL-103, a nicotinamide derivative, has been found to be an inhibitor of both histone deacetylases and hedgehog pathway. It was found to exhibit activity in decr...
GSK J4 HCl
GSK J4 HCl is a cell permeable prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM and i...
KDM5-IN-1 is a potent and selective KDM5 inhibitor with modest cell activity (PC9 H3K4Me3 EC50 = 5.2 μM).